NBI-74788
Sponsors
Neurocrine Biosciences Inc., Neurocrine Biosciences
Conditions
CAH - Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia (CAH)Congenital adrenal hyperplasia (CAH)
Phase 2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
CompletedNCT03525886
Start: 2018-04-10End: 2020-04-07Updated: 2022-05-03
A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia
RecruitingCTIS2024-514127-42-00
Start: 2025-10-16Target: 10Updated: 2025-11-11
Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Active, not recruitingCTIS2023-509170-33-00
Start: 2021-11-23Target: 35Updated: 2026-01-14
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Active, not recruitingCTIS2023-509171-16-00
Start: 2020-11-23Target: 99Updated: 2025-11-19
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
Not yet recruitingCTIS2025-524282-24-00
Target: 47Updated: 2026-07-24